Last update June 10, 2018
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Erdosteine is also known as
Erdosteine in other languages or writings:
Erdosteine belongs to this group or family:
Main tradenames from several countries containing Erdosteine in its composition:
|Oral Bioavail.||Alta - Hig||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A thiolactone derivative mucolytic agent of the natural amino acid homocysteine indicated in chronic obstructive bronchitis (CECMED 2017). Administered orally every 12 hours.
Since the last update we have not found published data on its excretion in breastmilk.
Its short half-life makes transfer to milk in significant quantities unlikely.
Side effects are gastrointestinal and mild.
This drug has very few bibliographic references and its effectiveness has not been proven (Cazzola 2018, Welsh 2015, Irwin 1993).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
If you wish to minimize exposure, you should wait about 3 hours to breastfeed after administration.